Kura Oncology
KURA
148 hedge funds and large institutions have $1.26B invested in Kura Oncology in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 44 increasing their positions, 52 reducing their positions, and 21 closing their positions.
207% more call options, than puts
Call options by funds: $3.49M | Put options by funds: $1.14M
120% more funds holding in top 10
Funds holding in top 10: 5 → 11 (+6)
13% more capital invested
Capital invested by funds: $1.11B → $1.26B (+$144M)
2.91% more ownership
Funds ownership: 100.12% → 103.03% (+2.9%)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
3% less funds holding
Funds holding: 152 → 148 (-4)
15% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20.6M |
| 2 |
CC
Commodore Capital
New York
|
+$15.1M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$11M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$9.51M |
| 5 |
TP
Thunderbird Partners
London,
United Kingdom
|
+$7.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$25.7M |
| 2 |
AWA
Aaron Wealth Advisors
Chicago,
Illinois
|
-$12.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$7.53M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$4.41M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$4.3M |
KURA Hedge Fund Activity: Q2 2022 in Review
148 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2022, worth a combined $1.26B — up 13% from $1.11B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of KURA and 19 opened new positions — a net loss of 2 holders — while 52 trimmed existing stakes and 44 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $20.6M. The largest seller was Deerfield Management, cutting an estimated $25.7M.
- 148 institutional investors held Kura Oncology (KURA) as of Q2 2022, down from 152 in Q1 2022.
- Funds reported $1.26B of Kura Oncology stock for Q2 2022, up 13% quarter-over-quarter.
- 19 funds opened new Kura Oncology positions in Q2 2022 and 21 closed out, a net change of -2 holders.
- The largest Kura Oncology buyer in Q2 2022 was Balyasny Asset Management, an estimated $20.6M added.
- The largest Kura Oncology seller in Q2 2022 was Deerfield Management, an estimated $25.7M sold.
Based on aggregated 13F filings for Q2 2022.